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ABSTRACT 
Liposomesof curcumin was prepared by Thin Film Hydration method (TFH) and Reverse Phase Evaporation Method (REV) methods and 
Freeze-thaw (F-T) cycles were carried out for liposomes prepared by both the methods, then optimized with regard to percentage drug 
entrapment by changing various process and formulation parameters, various compositions of optimized liposomal batches along with their 
PDE and mean vesicle size values are recorded. Prepared liposomes prior to size reduction were suitable for nasal delivery as then vesicle size 
distribution was in range of 10-20 pm that is required for nasal drug delivery. and finally optimized final batch parameter were evaluated and 
conclude ration of lipid and drug were-Drug: PC :CHOL (1:4:1), REV method followed by F-T cycles and Diethyl ether :water (5:1) solvent 
systems were used and  PDE/D[4,3] before size reduction was 97.89±0 31/ 12.8±0.2 and PDE/D[4,3] after size reduction 98.3 ± 0.21/2.5 ± 0.01 
were obtained. However, further processing for size reduction of liposomes was required for lung deposition in case of pulmonary drug deliver) 
and hence liposomes after size reduction to 3-5 pm were used for preparation of DPI formulations. 
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1. INTRODUCTION 
Liposomes were first reported as a particulate dispersion of 
solid spherical particles between 0.2-100 µm in diameter 
consisting of solid hydrophobic fat core such as triglycerides 
or fatty acids derivatives, stabilized by monolayer of 
phospholipids (Figure. 1). The internal core contains the 
drug dissolved or dispersed in solid fat matrix.  Liposomes 
represent a new type of fat based encapsulation system 
developed for parenteral and topical delivery of bioactive 
compounds.1-4 Inconsistent nomenclature is found in 
relation to Liposomes as nano-scale particles termed solid 
lipid nano particles (SLN). 
 
Figure 1: Structure of Liposomes 
                
Agents for agricultural applications such as herbicides, 
fungicides and fertilizers can also be incorporated into 
lipospheres.5-8 Lipospheres are distinct inner cores at room 
temperature. The lipospheres are distinct from 
microspheres of uniformly dispersed material in 
homogenous polymer since they consist of at least two 
layers, the inner solid particle and the outer layer of 
phospholipids.9  
2. DRUG PROFILE10-14: 
Curcumin is a phytopolylphenol pigment isolated from the 
plant Curcuma longa, commonly known as turmeric, with a 
variety of pharmacologic properties. Curcumin blocks the 
formation of reactive-oxygenspecies, possesses anti-
inflammatory properties as a result of inhibition of 
cyclooxygenases (COX) and other enzymes involved in 
inflammation; and disrupts cell signal transduction by 
various mechanisms including inhibition of protein kinase C. 
These effects may play a role in the agent's observed 
antineoplastic properties, which include inhibition of tumor 
cell proliferation and suppression of chemically induced 
carcinogenesis and tumor growth in animal models of 
cancer. 
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Figure 1: Chemical structure of Curcumin 
Table 1: Physiochemical Properties of Curcumin 
Properties Specifications 
IUPAC Name (1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione 
Molecular formula C21H20O6 
Mol. Wt. 368.385 g/mol 
Solubility Insoluble in water 
Color yellow 
Nature of particle A fine, white crystalline powder 
 
3. MATERIALS AND METHOD: 
Table 2: Chemicals used during the Experimental work 
Sr. No. Chemical/Material Source/Manufacturer 
1 Curcumin AK Scientific, San jose  
2 Ethanol Absolute ChangshuYanguan Chemicals, China 
3 α-Tocopherol Gateffose, India 
4 Egg yolk phaspholipid Thomas Baker Pvt. Ltd. 
5 Cholesterol  Thomas Baker Pvt. Ltd 
6 Methanol SD Fine-chem Ltd, Mumbai 
7 HCl SD Fine-chem. Ltd, Mumbai 
8 n-octanol SD Fine-chem. Ltd, Mumbai 
 
3.1 Preformulation Studies: 
3.1.1 Melting point determination: 
Capillary fusion method was used to determine the melting 
range of the drug.15 
3.1.2 Solubility study 
a) Lipid solubility: 100 mg of lipids were taken in culture 
tube and placed them in water bath shaker at 80°C and kept 
shaking until they melt. An excess amount of drug was added 
while shaking meanwhile 4 ml of distilled water was added 
and allowed their shaking for 72 h at 80°C. After 72 h 
centrifuge the sample at 15000 rpm followed by taking the 
supernatant and diluted with methanol if required. Scan the 
sample in UV spectroscopy between 200-400nm.16 
b) Solvent solubility: Took 2 ml of each solvent in culture 
tube. Add excess amount of drug in 2 ml of solution using 
vortex shaker. Put the solution into water bath shaker for 48 
h at 37°C. After 48 h. centrifuge the sample at 15000 rpm 
followed by taking the supernatant and diluted with suitable 
solvent if required. Scan the sample in UV spectroscopy UV 
spectroscopy (Shimadzu UV spectrophotometer, Japan) 
between 200-400 nm.17-18 
3.1.3 Partition coefficient  
A saturated solution of Curcuminwas prepared. And the 
above formed mixture was left undisturbed for about 24 h. 
Two layers were separate through separating funnel and the 
amount of solubilized Curcuminwas determined by 
measuring the absorbance at 320 nm against methanol blank 
through double beam UV/Vis spectrophotometer (Shimadzu) 
in both the solution. Partition coefficient was determined as 
ratio of concentration of drug in n-octanol to the 
concentration of drug in water and the value were reported 
as log P.19 
P o/w = Cn (octanol)/Co (water) 
3.1.4 Drug excipients compatibility study by FTIR 
The compatibility of drug with excipients was ascertained by 
FT-IR. FTIR was used as tool to detect any physical and 
chemical interaction between drug and excipients.20 
3.1.5 UV spectrum of Curcumin in Methanol 
Double beam UV-visible spectrophotometer (Shimadzu 
Corporation, UV–1800, Kyoto, Japan) was used to determine 
the λmax of drug. A stock solution of the drug (100 μg/ml) in 
methanol was prepared. The sample was then diluted with 
methanol (25 μg/ml). The resulting solution was scanned in 
the range 200-400 nm to determine the λmax of the drug 
Curcuminexhibited characteristic λmax at 320 nm.21 
4. PREPARATION OF CURCUMIN LIPOSOMES: 
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The liposomes of curcumin were prepared by two methods 
viz, 
(i) Thin Film Hydration method (TFH)22-24 and  
(ii) Reverse Phase Evaporation Method (REV)25 methods. 
4.1 Thin Film Hydration method (TFH): 
EggPC/CHOL, curcumin & α-tocopherol (equivalent to 1% 
w/w of PC) in 5 ml chloroform/methanol (2:1) in 250 ml 
round bottom flask (Quick 111 neck B-24) Smooth, dry lipid 
film formation using rotary Hash evaporator at 120 rpm, 
vacuum of 500 mini Ig at 30°C The nitrogen atmosphere was 
maintained. Hydration of film carried out with the 0.5 mL 
double distilled water. Annealing of liposomes at room 
temperature at 2 hrs, separation of un-intrapped drug using 
centrifugation and Liposomes loaded with drug subjected for 
characterization. 
4.2 Reverse Phase Evaporation Method (REV Method): 
EggPC/CHOL, Curcumin & α-tocopherol (equivalent to 1% 
w/w of PC) in 2.5 ml of Diethyl ether in a glass boiling lube 
(Quick Fit neck B-24). 0.5 mL of double distilled water 
injected rapidly with force using 23-gauge hypodermic 
needle attached to 5 ml syringe. Boiling tube closed with 
glass stopper; sonicated for 5 minutes in bath sonicator, 
attach this tube to rotary' flash evaporator to dry' the 
contents at 37 °C under vacuum of 500 mmHg until gel form. 
Vacuum released, tube removed frorn evaporator and 
subjected to vigorous mechanical agitation on vortex mixer 
for 5 minutes. When gel collapsed to fluid, boiling tube fitted 
again to rotary' flash / evaporator for removal of organic 
solvent. A cycle of 10 minutes drying and 5 minutes 
vortexing repeated twice. Final liposomal suspension 
subjected for removal of last traces of organic solvent under 
high vacuum (500 mmHg) for 15 minutes then separation of 
un-entrapped drug using centrifugation and Liposomes 
loaded with drug subjected further for characterization. 
5. EVALUATION PARAMETERS: 
5.1 Liposome Morphology: 
Transmission Electron Microscopy (TEM) was used to study 
the vesicles’ morphology. According to morphological 
evaluation analysis, all vesicle types seemed to have a similar 
spherical or oval shape. These oval-shaped vesicles may have 
resulted from the liposomes’ deformation, which might occur 
during the sample preparation. In addition, TEM failed to 
reveal any structural differences among these vesicle types, 
indicating that phospholipid type did not have a significant 
impact on vesicle structure.26 
5.2 Differential Scanning Calorimetry: 
Characterization Differential Scanning Calorimetry (DSC) is 
used to characterize the melting and crystallization behavior 
of crystalline materials. The DSC curves of curcumin, the 
physical mixture with or without curcumin, and three kinds 
of curcumin-loaded liposomes were recorded.27 
5.3 Determination of vesicle Size:  
The vesicle size determination of the prepared liposomes 
carried out by light scattering was based on laser diffraction 
using Malvern. MasterSizer SM 2000k (Malvern Instillments 
Inc, UK).28 
5.4 Determination of vesicular shape & lamellarity:  
All the batches of the liposomes alter sufficient dilution were 
viewed under Olympus (BX 40F4, Japan) with the provision 
of dark background and attachment of polarizing lens, to 
study their shape and lamellarity.29 
5.5 Determination of Percentage of entrapment 
efficiency (PDE)30-31: 
The mini-column centrifugation method was used to assay 
entrapment efficiency. Sephadex G50 was chosen, swollen in 
distilled water for at least 12 h and stored at 4 °C. A small 
piece of cotton was inserted in the bottom of the barrels of a 
2 cm3 injection syringe, which was then filled with sephadex 
G50. Excess water was centrifuged off at 1,500 rpm for 3 
min, and 0.5 mL PBS (pH6.5) was added, then centrifugation 
repeated twice. An equal volume of curcumin-loaded 
liposome suspension was also determined and the calculated 
drug amount was designated as WTotal:  
% drug entrapeed (PDE)=  WEntrapped/ WTotalX100 
5.6 In vitro drug release study from liposomes: 
Concentrated liposomal suspension, 0.5 ml was taken in a 
test tube of opening diameter of 20 mm. The open end was 
covered with a semi-permeable dialysis membrane (Himedia 
Laboratories Pvt. Ltd.) and tied with a thread. The test tube 
was inverted and placed over the surface of 100 ml water 
present in a 250 ml beaker in such a way that the membrane 
just touched the water surface. The test tube was secured by 
a clamp fixed with a stand. The water in the beaker was 
stirred with a magnetic stirrer so that no vortex could form 
in the beaker. The temperature was maintained at 37 °C. The 
drug released from the liposomes permeates across the 
membrane and enters into the receptor chamber medium. 
Samples of 2 ml were taken out from the receptor chamber 
medium, suitably diluted, and the absorbances were taken by 
UV-spectrophotometer at 320 nm against a blank of fresh 
medium.32-33 
6. RESULTS & DISCUSSION 
6.1 Organoleptic properties: 
Organoleptic properties of drug Curcumin found to be as per 
I.P. monograph.  
Table 3: Organoleptic Properties of Curcumin 
Sr. no. Properties Inferences 
1 Colour Yellow   
2 Odour Odourless 
3 Form Crystalline 
4 Melting point 181-184° C 
5 Log p Values 3.230± 0.061 
 
Table 4: Solubility studies of Curcumin for different lipids 
S. No Lipid Name Solubility (mg/ml) Mean±S.D 
1 EPC 14.048±0.002 
2 Cholesterol 13.723±0.058 
3 Α-tocopherol 14.645±0.004 
 
Table 5: Solubility studies of Curcumin for different lipids 
S. No Solvent Name Solubility (mg/ml) Mean±S.D 
1 Methanol 59.238±0.872 
2 Ethanol 38.857±0.571 
3 0.1N HCl 0.198±0.001 
4 PBS 6.8 0.041±0.0003 
5 PBS 7.4 0.001±0.0003 
6 Chloroform 44±0.571 
7 Acetone 51.619±0.872 
* Each value is average of three independent determinations 
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Figure 2: Solubility study of drug in different solvents 
6.2 Drug Excipient compatibility study by FTIR 
 
Figure 3: FTIR spectra of standard curcumin 
 
Figure 4: FTIR spectra of physical mixture containing drug and PC 
 
6.3 Determination of absorption maxima in Methanol: 
Table 6: Calibration curve of Curcumin in Methanol (λmax = 
320 nm) 
S. No. Concentration (μg/ml) Absorbance (Mean ±SD) 
1 1 0.052±0.003 
2 5 0.195±0.002 
3 10 0.412±0.003 
4 15 0.551±0.001 
5 20 0.767±0.002 
6 25 0.899±0.005 
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Figure 6: Graph of standard calibration curve of Curcumin 
in Methanol 
 
7. EVALUATION PARAMETER: 
7.1 Effect of Melting Point on Combination of Lipid And 
Drug: 
The melting points for the three kinds of physical mixture I 
(PC:Curcumin) were found to be generally between 126.8°C 
and 143.6°C. Curcumin alone exhibited a melting peak of 
approximately 182.3o C. The physical mixture with curcumin 
showed a melting point of approximately 179.3o C; however, 
this phenomenon was not observed in liposomes. Moreover, 
the melting point of lipid material in the three kinds of 
liposomes dropped 6–17 °C compared with the 
corresponding physical mixtures I and II (CHOL:Curcumin). 
7.2 Effect of Process Variables: 
Table 7: Selection of Process Variables for Preparation of 
Curcumin Liposomes 
Independent Variables Level 
1 2 3 
Chloroform methanol ratio 2.1 1.1 1.2 
Vacuum 400 500 600 
Speed of rotation 80 120 160 
Temperature  20 30 40 
 
7.3 Influence of F-T cycles: 
Influence of F-T cycles on PDF of liposomes were also 
evaluated and PDF before and after exposure of liposomes to 
FT cycles are recorded in table 8. Significant improvement in 
PDF was observed after exposure of liposomes to F-T cycles 
Significant variation (p<0.05) variation in vesicle size after 
F-T cycle was observed. 
 
Table 8: Influence of Frecze-thaw cycles on Percent Drug Entrapment of curcumin liposomes 
Batch Molar ratio 
(Drug PC CHOL) 
TFH Method PDF ± SEM REV Method PDF ± SEM 
1 1:2:0                          B 5 765±2 25 8 254+2 00 
A1 11 54+1 21 15 67+0 74 
A2 15 13+0 58 15 85+0 41 
A3 15 25+0 42 15 25+0 42 
2 1:3:0                          B 16 25±2 35 2 i 08+2 52 
A1 35 43±2 13 43 87+0.11 
A2 42 69+0 97 44 38+0 79 
A3 43.847+0.37 44 254+0 35 
3 1.4:0                          B 71.23+2 45 78 650+2 69 
A1 88 32+1 18 96 98+1 09 
A2 96 10+0 65 97 32+0.45 
A3 96 02+0 31 97 56+0.29 
4 1:5:0                          B 74 36+2.69 83 32+2 87 
A1 91 31+201 95 61+0.98 
A2 95 86+1 08 96 56+0 25 
A3 95 98+0 28 96 69+0 26 
5 1:4:1                          B 76.275+3 15/15.0+0 2* 88 789+3 00/12 6+0.2* 
A1 89 54+2.54 97 98+1.36 
A2 96 87+1 17 99 01+0.44 
A3 97.98+0.29 98.99+0 21 
6 1:3:2                          B 35 014+2 11 40 519+2 31 
A1 49 23+1.16 ' 55 36+1.21 
A2 57.01+0.74 56 45+0.47 
A3 58 321+0.21 56 551+0.26 
*D[4,3], B=Before Freeze thaw Cycle, Al= After 1st Freeze thaw cycle A2= After 2nd Freeze thaw cycle, A3= After 3rd Freeze 
thaw cycle. 
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Table 9: Effect of Hydration time on PDE of liposomes prepared by TEH and REV method 
TIme of Hydration TFH method REV method 
2 68 14+3 17 88 7S9±3.00 
4 76 27±3 15 88 71512 86 
8 76 29±3 21 -- 
12 -- -- 
 
Table 10: Effect of time and temperature of freezing on PDE evaluated in Batch 05 
Time/temperature TFH method REV method 
Before 76 2717 73 88 79±7 35 
30 min/-20°C 76 32±7 45 87 98±6 98 
60 min/-20°C 78 65±2 13 88 67±0 98 
120min/-20°C 79.54±1 21 89 98±0 32 
180 min/-20°C 79 24±I 12 97 0110.29 
30min/-40°C 77 96±6 83 89 1316 42 
60min/-40°C 88 13± 1 05 96 6110.78 
120min/-40°C 89.49+0.98/15.1+0.2* 97.89+0.31/ 12.8+0.2* 
* D,[4,3] 
Table 11: Effect of Post Sonication Freeze-thaw cycle on Batch 05 
Sonication Time PDE before Freeze-thaw cycle/ 
Liposome size (D[4,31) 
PDF after Freeze-thaw 
cycle/Liposome size (D[4,3]) 
0 min -- 98 3±02ll/128±02 
10 min 84 14± i 26/8 4 ±0 14 9 98 27 ± 0 20/8 5 ± 0.03 
20 min 72 06± I 15/2 5±0 II 98 3 ± 0 21/2 5 ± 0 01 
30 min 37.34± I 51/2 1 ±0 II 88 29 ± 0 35/2 2 ± 0 11 
 
7.4 Size Reduction of Optimized Liposomal batch (Batch 
05): 
Size reduction of curcumin liposome was carried out using 
sonication in a 10 ml borosil beaker under ice bath, b) probe 
sonicator Twenty minutes sonication lime was found to be 
optimum with' regard to required size distribution (below 5 
pm) Post sonication F-T cycles helps in regaining the 
equilibrium with the leaked drug. 
 
      
Before F-T cycle                                                     After F-T cycle 
Figure 7: Photomicrographs of the optimized liposomal batches 
 
                  
A      B                                      C 
Figure 8: Morphology of curcumin-loaded liposomes.(A) PC:Drug, (B) CHOL:Drug (C) PC:CHOL:Drug 
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7.5 Differential scanning colorimeter (DSC) Analysis: 
 
Figure 9: Differential Scanning Calorimetric Thermogram of PC, CHOL, Curcumin and physical mixture of PC:CHOL:Curcumin 
 
7.6 Comparisons of all formulation:  
The curcumin liposomes prepared by two different methods 
compared, REV method showed higher PDE at all the drug: 
PC: CHOL ratio compared to TFH method. The high 
entrapment found for MLV vesicles prepared from 
water/organic solvent emulsions (REV method) depend on 
maintaining a core dining the process of liposome formation 
(Prdgeon et al„ 1987) Even during the Freeze-thaw cycles, 
equilibrium with respect to PDE attained faster (after FT 
cycle) for REV method compared to that of TFH method 
(after 3rd cycle) The difference in number of freez thaw 
cycles required to establish equilibrium on prepared 
liposomes for both the methods, may be due to the structural 
differences observed for liposomes produced by both the 
methods as TFH method resulted into multillamellar and 
REV method resulted into oligolamellar liposomes. 
Table 12: Analytical profile of Final Liposomal batches of 
curcumin 
Batch Curcumin Liposomes  
Composition Drug: PC :CHOL (1:4:1) 
Method of Preparation REV method followed by F-T cycles 
Solvent system Diethyl ether :water (5:1) 
PDE/D[4,3] before size 
reduction 
97.89±0 31/ 12.8±0.2 
PDE/D[4,3] after size 
reduction 
98.3 ± 0.21/2.5 ± 0.01 
 
8. CONCLUSION: 
On physicochemical evaluation melting point and partition 
coefficient was found to be 181-184°C and 3.230± 0.061 and 
it shows that the curcumin is lyophilic in nature. On FTIR 
spectroscopy and DSC analysis, there was no incompatibility 
between drug and lipid. On UV-visible spectrophotometer 
analysis absorption maxima of Curcumin was found to be 
420 nm. Drug was freely soluble in methanol followed by 
chloroform and acetone. Liposomesof curcumin was 
prepared by Thin Film Hydration method (TFH) and Reverse 
Phase Evaporation Method (REV) methods and Freeze-thaw 
(F-T) cycles were carried out for liposomes prepared by both 
the methods, then optimized with regard to percentage drug 
entrapment by changing various process and formulation 
parameters, various compositions of optimized liposomal 
batches along with their PDE and mean vesicle size values 
are recorded. Prepared liposomes prior to size reduction 
were suitable for nasal delivery as then vesicle size 
distribution was in range of 10-20 pm that is required for 
nasal drug delivery. 
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